STEPHEN LACAZE: Open Payments
NPI 1023596053 · IOTA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,608 in 70 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $425 · 2025 $1,608
Food & beverage: $1,608
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 12 | $318 |
| Axsome Therapeutics, Inc. | 9 | $237 |
| ABBVIE INC. | 8 | $236 |
| Vanda Pharmaceuticals Inc. | 7 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $112 |
| Lilly USA, LLC | 5 | $92 |
| Abbott Laboratories | 3 | $75 |
| Amgen Inc. | 4 | $73 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $64 |
| Verona Pharma, Inc. | 2 | $39 |
Products named: IBSRELA, Auvelity, VRAYLAR, FANAPT, CAPLYTA, MOUNJARO, FREESTYLE LIBRE 3, EVENITY.
Industry payments across LA — which companies pay providers there.
